The client is a pharmaceutical company that is involved in research and development through manufacturing and sales, such as providing small molecule drugs and antibody drugs for solid tumors and hematological malignancies. The company positions oncology as one of the higher-priority areas in R&D and aims to create innovative new drugs for diseases with a low treatment satisfaction.
Although R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is used as a first-line treatment for DLBCL and exhibits a certain level of response rates, there are issues such as recurrence and acquisition of resistance and there is still a high unmet medical needs.
The client aims to develop drugs for treatment of DLBCL whose combinational effects with R-CHOP therapy can be expected or whose efficacy in patients resistant to R-CHOP therapy can be expected. The client has thus issued this open request in order to accelerate the clinical application of a new treatment drug in cooperation with potential organizations with promising candidate.
ANTICIPATED PROJECT PHASES OR PROJECT PLAN
Respondents should submit proposals using the attached Response Template.
The client will review submitted proposals and possibly ask clarifying questions before selecting the most suitable candidates for collaboration. The client will select the best candidate(s) through evaluations. During the selection process, the client may execute non-disclosure agreements (NDA) with selected respondent(s), seek further information disclosure, and discuss specific development targets or potential opportunities. The client will execute necessary agreement(s) with the selected respondent(s) and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.